Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SUCNR1 | Q9BXA5 | 9/20 | 0.44 |
| ▸ | OXGR1 | Q96P68 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6129289 | 0.87 | KCNH2 (0.55) | PDE10AALDH1A1SUCNR1OXGR1TDP1 | |
| SCHEMBL4823229 | 0.84 | ALDH1A1 (0.48) | PDE10AALDH1A1KDM4ELMNAMEN1 | |
| SCHEMBL23083184 | 0.83 | PDE10A (0.49) | PDE10AALDH1A1KDM4ELMNAMEN1 | |
| SCHEMBL28337161 | 0.83 | PDE10A (0.48) | PDE10AALDH1A1KDM4ELMNAMEN1 | |
| SCHEMBL20156313 | 0.83 | HRH1 (0.50) | PDE10AALDH1A1KDM4ELMNAMEN1 | |
| SCHEMBL27705784 | 0.83 | PDE10A (0.48) | PDE10AALDH1A1KDM4ELMNAMEN1 | |
| SCHEMBL21784747 | 0.82 | PDE10A (0.46) | PDE10AALDH1A1KDM4ELMNAMEN1 | |
| SCHEMBL6899530 | 0.80 | SUCNR1 (0.47) | PDE10AALDH1A1SUCNR1OXGR1 | |
| SCHEMBL276117 | 0.80 | SUCNR1 (0.50) | PDE10AALDH1A1KDM4ELMNAMEN1 | |
| SCHEMBL20481012 | 0.80 | SUCNR1 (0.47) | PDE10AALDH1A1LMNASUCNR1OXGR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| WO-2018089357-A1 | INDAZOLE DERIVATIVES AS αV INTEGRIN ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
| US-7879863-B2 | Kallikrein inhibitors such as N-((2R)-3-methyl-2-{[4-(trifluoromethyl)phenyl]amino}butyl)-2-phenylacetamide trifluoroacetate, used for the treatment of gastrointestinal disorders, periodontal diseases, skin disorders, arthritis, hypotension, edema, respiratory system disorders and proliferative diseases | AJINOMOTO CO., INC. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20070066586-A1 | ANILINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066586-A1 | ANILINE DERIVATIVES | SERPINB1, ACE, REN | PDE10A 1240/4885ALDH1A1 747/4885KDM4E 965/4885 |
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | PDE10A 909/4885ALDH1A1 4677/4885KDM4E 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.